| Literature DB >> 29237409 |
Daisuke Takada1, Keiichi Sumida1, Akinari Sekine2, Ryo Hazue1, Masayuki Yamanouchi1, Tatsuya Suwabe1, Noriko Hayami1, Junichi Hoshino1, Naoki Sawa1, Kenmei Takaichi1,3, Takeshi Fujii4, Kenichi Ohashi4,5, Yoshifumi Ubara6,7.
Abstract
BACKGROUND: Various renal manifestations are known to develop in patients with liver disease, including chronic hepatitis and cirrhosis. CASEEntities:
Keywords: Alcoholic cirrhosis; IgA nephropathy; Wire loop-like subendothelial deposit
Mesh:
Substances:
Year: 2017 PMID: 29237409 PMCID: PMC5729455 DOI: 10.1186/s12882-017-0769-1
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Laboratory findings of case 1 before and after 1 year of steroid therapy
| Before | After 1 year | Normal range | |
|---|---|---|---|
| White blood count, /μl | 4600 | 6600 | 3400–9200 |
| Red blood cell, ×10*4/μl | 4.2 | 2.61 | 400–566 |
| Hemoglobin, g/dl | 13.4 | 9 | 13.0–17.0 |
| Hematocrit, % | 41.3.6 | 28 | 38.2–50.8 |
| Platelet, ×10*4/μl | 17.6 | 13 | 14.1–32.7 |
| Total protein, g/dl | 5.5 | 6.8 | 6.9–8.4 |
| Albumin, g/dl | 2.2 | 2.7 | 3.9–5.2 |
| Total bilirubin, mg/dl | 1.5 | 2.6 | 0.3–1.1 |
| AST, IU/l | 60 | 70 | 13–33 |
| ALT, IU/l | 38 | 36 | 8–42 |
| LDH, IU/l | 204 | 250 | 119–229 |
| CPK, IU/l | 62 | 42 | 62–287 |
| ALP, IU/l | 232 | 304 | 117–350 |
| γGTP, IU/l | 140 | 358 | 9–109 |
| LAP | 54 | 63 | 21–42 |
| ChE | 184 | 143 | 220–495 |
| T-Chol | 174 | 210 | 120–240 |
| TG | 76 | 151 | 30–150 |
| NH3 | 91 | 62 | 6–51 |
| HbA1c | 4.7 | 4.6–6.2 | |
| UN, mg/dl | 17 | 17 | 8–12 |
| Creatinine, mg/dl | 0.9 | 1.1 | 0.65–1.06 |
| eGFR | 72.1 | 57.9 | >100 |
| Urinary acid, mg/dl | 6.5 | 7.7 | 2.5–7.0 |
| Na, mmol/l | 140 | 139 | 139–146 |
| K, mmol/l | 4.2 | 4 | 3.7–4.8 |
| Cl, mmol/l | 104 | 102 | 101–108 |
| APTT, sec | 41.7 | 31.1 | 27–40 |
| PT,% | 79.4 | 53.2 | >75 |
| INR, | 1.15 | 1.3 | |
| ICG15R(%) | 58 | 32 | <10 |
| IgG, mg/dl | 740 | 947 | 870–1700 |
| IgA, mg/dl | 1110 | 845 | 110–410 |
| IgM, mg/dl | 162 | 190 | 35–220 |
| IgE, mg/dl | <173 | ||
| C3, mg/dl | 66 | 78 | 86–160 |
| C4, mg/dl | 13 | 15 | 17–45 |
| CH50, U/ml | 31 | 35 | 30–50 |
| ANA | negative | negative | |
| anti ds-DNA | negative | negative | |
| anti RNP | negative | negative | |
| anti mitochondria | negative | negative | |
| Cryoglobulin | negative | negative | |
| HCV | negative | negative | |
| HBV | negative | negative | |
| CRP, mg/dl | 0.1 | 0.1 | 0.0–0.3 |
| Urinalysis | |||
| Sediment | |||
| RBC /HPF | many | 1 to 4 | <1 |
| WBC /HPF | 6–10 | – | <1 |
| Cast | None | None | <1 |
| protein, g/day | 3.94 | 0.04 | <0.1 |
| Glucose | negative | negative | negative |
| NAG, IU/day | 14.3 | 8.9 | 0.8–5.0 |
| α1 MG, mg/day | 8.1 | 2.1 | 0.6–8.8 |
| β2 MG, mg/day | 46 | 30 | 14–329 |
Laboratory findings of case 2 before and after 1 year of steroid therapy
| Before | After 1 year | Normal range | |
|---|---|---|---|
| White blood count, /μl | 10,300 | 8700 | 3400–9200 |
| Red blood cell, ×10*4/μl | 4.14 | 3.95 | 400–566 |
| Hemoglobin, g/dl | 12.4 | 11.1 | 13.0–17.0 |
| Hematocrit, % | 36.6 | 34.5 | 38.2–50.8 |
| Platelet, ×10*4/μl | 14.7 | 18.6 | 14.1–32.7 |
| Total protein, g/dl | 6 | 6.5 | 6.9–8.4 |
| Albumin, g/dl | 2.7 | 2.8 | 3.9–5.2 |
| Total bilirubin, mg/dl | 0.6 | 0.5 | 0.3–1.1 |
| AST, IU/l | 65 | 32 | 13–33 |
| ALT, IU/l | 38 | 10 | 8–42 |
| LDH, IU/l | 231 | 234 | 119–229 |
| CPK, IU/l | 118 | 94 | 62–287 |
| ALP, IU/l | 298 | 298 | 117–350 |
| γGTP, IU/l | 172 | 63 | 9–109 |
| LAP | 54 | 21–42 | |
| ChE | 204 | 220–495 | |
| T-Chol | 172 | 137 | 120–240 |
| TG | 111 | 167 | 30–150 |
| NH3 | 31 | 38 | 6–51 |
| HbA1c | 4.9 | 4.6 | 4.6–6.2 |
| UN, mg/dl | 23 | 21 | 8–12 |
| Creatinine, mg/dl | 1.66 | 1.55 | 0.65–1.06 |
| eGFR | 36.8 | 47.5 | |
| Urinary acid, mg/dl | 9.3 | 6.7 | 2.5–7.0 |
| Na, mmol/l | 144 | 141 | 139–146 |
| K, mmol/l | 4.2 | 5 | 3.7–4.8 |
| Cl, mmol/l | 107 | 110 | 101–108 |
| APTT, sec | 25.9 | 30.9 | 27–40 |
| PT,% | 99.3 | 89.5 | >75 |
| INR, | 1 | 1 | |
| ICG15R(%) | 27 | ||
| IgG, mg/dl | 958 | 1195 | 870–1700 |
| IgA, mg/dl | 519 | 324 | 110–410 |
| IgM, mg/dl | 149 | 1216 | 35–220 |
| IgE, mg/dl | 88.9 | <173 | |
| C3, mg/dl | 62 | 89 | 86–160 |
| C4, mg/dl | 17 | 37 | 17–45 |
| CH50, U/ml | 34 | 42 | 30–50 |
| ANA | negative | negative | |
| anti ds-DNA | negative | negative | |
| anti RNP | negative | negative | |
| anti mito | negative | negative | |
| Cryoglobulin | negative | negative | |
| HCV | negative | negative | |
| HBV | negative | negative | |
| CRP, mg/dl | 0 | 0 | 0.0–0.3 |
| Urinalysis | |||
| Sediment | |||
| RBC, /HPF | many | 1 to 4 | <1 |
| WBC, /HPF | 1–4 | – | <1 |
| Cast | None | None | <1 |
| protein, g/gCre | 1.17 | 0.01 | |
| Glucose | negative | negative | negative |
| NAG, IU/day | 14.3 | 8.9 | 0.8–5.0 |
| α1 MG, mg/day | 8.1 | 0.4 | 0.6–8.8 |
| β2 MG, mg/day | 14 | 19 | 14–329 |
Fig. 1a: Case 1: Light microscopy (LM) of the first renal biopsy specimen shows massive subendothelial wire loop-like deposits of amorphous material in the glomerular basement membrane (GBM) and similar deposits the mesangium. b: Immunofluorescence (IF) is positive for IgA(IgA1 > IgA2) and C3, predominantly in the mesangium and GBM. c: Electron microscopy (EM) shows huge subendothelial electron-dense deposits (EDD) without an organized internal structure in the GBM and similar deposits in the mesangium. d: LM of the second renal biopsy specimen demonstrates marked improvement of the glomerular changes. e: IF shows weaker staining for IgA and C3 compared to that seen in the first biopsy. f: EM reveals disappearance of the massive EDD
Fig. 2a: Case 2: LM of the first renal biopsy specimen demonstrates massive wire loop-like deposits of amorphous material similar to those seen in case 1. b: IF displays similar findings to case 1. c: EM reveals massive deposits similar to those seen in case 1. d: LM of the second renal biopsy specimen shows marked improvement of the glomerular changes. e: IF displays weaker staining for IgA and C3 compared to the first biopsy. f: Massive EDD are no longer shown by EM